Transforming Elderly and Rare Cancers Through Smart Information Sharing in Trials
Official title: Transforming Clinical Trials for Elderly and Rare Cancers through Intelligent and Robust Information Borrowing
Funded at North Carolina State University Raleigh · NIH-11448693 · Data updated 2026-11-12
This grant develops new trial designs and data methods to make cancer trials more reliable and generalizable for elderly patients and rare cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | North Carolina State University Raleigh NIH-funded |
| Lab location | 1 site (Raleigh, United States) |
| Project start | May 1, 2020 |
| Project end | April 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $465,815 |
| NIH project number | 2R01AG066883-05A1 |
| Project ID | NIH-11448693 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with early-stage cancers, rare tumors, or elderly individuals who participate in or could participate in clinical trials.
✕Less likely to help
This grant focuses on statistical methods; individual patient benefit depends on future trials that apply these methods to specific treatments.
What this research studies
This project focuses on innovative clinical trial designs like basket, platform, and hybrid trials to improve how we test cancer treatments in small or heterogeneous patient groups. It aims to use real-world data and advanced analytics to make trial results more applicable to diverse patients, including the elderly and those with rare tumors. The team will create and validate robust statistical methods to handle heterogeneity and small sample sizes, enabling clearer conclusions about treatment effects while preserving trial efficiency. The work involves methodological research that could influence how future trials are designed and analyzed for cancer patients.
Why it matters
Potential benefit: If successful, the methods could make cancer trials more accurate and relevant for elderly and rare cancer patients, speeding access to effective treatments.
How similar studies have gone: Previous work has shown that real-world data and advanced trial designs can improve external validity and efficiency, with growing adoption in oncology.
Where this research is happening
-
North Carolina State University Raleigh
Raleigh, United States Active
Researchers
- Principal investigator: Yang, Shu — North Carolina State University Raleigh
- Study coordinator: Yang, Shu
Related research
Other NIH-funded projects on the same topics.
-
Brewing anti-toxin drugs using probiotic yeast
A studying team will develop probiotic yeast–based anti-toxin drugs to help treat gut bacterial infections and reduce antibiotic-related complications.
-
Small Ruminant Therapeutic Center to Speed Safe Drugs for Sheep and Goats
A pilot project at a university will help scientists and veterinarians speed up and improve how drugs are tested and approved for sheep and goats.
-
Metabolic effects of PFAS exposure in the Cape Fear Basin (GenX Exposure Study)
This NIH grant studies how PFAS chemicals in drinking water may affect metabolism and weight-related health in adults and children living along the Cape Fear River.
-
Understanding how Fe/2OG enzymes make pharmacophores like cyclopropane, aziridine, and isonitrile groups
A research project at a university aims to uncover how nonheme-iron enzymes create key drug-building rings and groups to help develop better biocatalysts and medicines.
-
Hemostatic B-knob Microgels for Pediatric Bleeding
A kid-friendly hemostatic therapy using age-tuned microgels to stop dangerous bleeding after injury in children.
-
How cyanotoxins may harm nerve cells in ALS
This grant studies how shared toxins from cyanobacteria might worsen nerve damage in people with ALS.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.